Abstract
Introduction: It has been proposed that oxidative stress plays a crucial role in vancomycin-induced nephrotoxicity (VIN). Objectives: The present study aimed to investigate the nephroprotective effects of lycopene, as a powerful antioxidant, on VIN. Patients and Methods: In the present study, individuals who received vancomycin (VCM) for any indication were assigned to drug (n=28) and control (n=30) groups. The individuals in the drug group received 25 mg of oral lycopene daily for 10 days started concurrently with VCM and the patients in the placebo group received placebo tablets with VCM. Serum levels of creatinine (SCr) and blood urea nitrogen (BUN) as well as creatinine clearance (CrCl) were determined and recorded before the start of interventions, every other day during therapy, and 12 hours after the last dose of VCM in 10th day of treatment for all participants. Finally, the mean values of the measured parameters were compared between the groups. Results: The mean values of SCr were significantly lower in drug group compared to placebo at the 4th (0.85 ± 0.18 vs. 0.98 ± 0.22, P=0.016) and 6th (0.83 ± 0.18 vs. 0.95 ± 0.21, P=0.029) days. Also, CrCl was significantly higher in the drug group at the 4th day compared to placebo (105.82 ± 20.09 vs. 94.67 ± 20.53, P=0.041). Regarding VCM-induced AKI, no case was reported in any group. Conclusion: Lycopene has the potential for diminution of VCM-induced nephrotoxicity (VIN). However, more investigations with larger sample size are necessary to confirm this effect.
Highlights
It has been proposed that oxidative stress plays a crucial role in vancomycininduced nephrotoxicity (VIN)
Lycopene has the potential for reduction of VIN
Patients and Methods Study design The present double-blind randomized placebo-controlled clinical trial was performed from September 2019 to February 2020 in infectious diseases department of Alzahra hospital, Isfahan, Iran affiliated to Isfahan University of Medical Sciences (IUMS)
Summary
It has been proposed that oxidative stress plays a crucial role in vancomycininduced nephrotoxicity (VIN). Objectives: The present study aimed to investigate the nephroprotective effects of lycopene, as a powerful antioxidant, on VIN. Results: The mean values of SCr were significantly lower in drug group compared to placebo at the 4th (0.85 ± 0.18 vs 0.98 ± 0.22, P = 0.016) and 6th (0.83 ± 0.18 vs 0.95 ± 0.21, P = 0.029) days. Vancomycin (VCM) is a bactericidal antibiotic with a molecular weight of 1.446 kD that stops the synthesis of cell wall in gram-positive bacteria (GPB) [1] This antibiotic is a keystone drug for the management of severe infectious conditions caused by GPBs. Prescription of VCM is effective for management of bacterial infections that triggered by Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus viridans, Clostridium, Corynebacterium, Staphylococcus aureus, and certain bacillus species [2,3,4]. Due to the key role of oxidative stress in the pathogenesis of VIN, treatment with natural antioxidants is considered as a potntially useful therapeutic option
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
